The Daily Buyout
$2.2BStrategic acquisitionHealthcare & Life Sciences

J&J to buy eye-disease biotech Ollin for $2.2B upfront

Johnson & Johnson has agreed to acquire Ollin Biosciences, a privately held, Austin-based clinical-stage company developing therapies for serious eye diseases, for $2.2 billion upfront. Up to about $1.1 billion more could follow in regulatory and commercial milestone payments. J&J will also sign a separate development funding agreement with Blackstone Life Sciences.

Why it matters: The deal gives J&J a late-stage bispecific antibody in ophthalmology that it says has best-in-class potential.

Read the full coverage, free

We only link to sources you can read without a subscription. How we check.

Following healthcare M&A?

The next big healthcare deal will be in our email the morning after it's announced, with the rest of the day's biggest deals. Free, with no paywalled links.

Free · Unsubscribe anytime

See what you get →